# A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

> **NCT06697197** · PHASE1,PHASE2 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 413 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** BMS-986482
- **DRUG:** Nivolumab and rHuPH20
- **DRUG:** Nivolumab/relatlimab/rHuPH20
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06697197
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-17
- **Primary completion:** 2029-01-04
- **Final completion:** 2029-01-05
- **Target enrollment:** 413 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06697197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06697197, "A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06697197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*